{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:09:18Z","timestamp":1778868558727,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The recent restriction on the use of fluoroquinolones for prophylaxis by the European Commission has left a gap in clear recommendations for practical antibiotic prophylaxis (PAP) for transrectal prostate biopsy (TRPB). This analysis investigated the viability of cotrimoxazole for PAP in TRPB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This analysis included <jats:italic>n<\/jats:italic>\u2009=\u2009697 patients who underwent TRPB for suspected prostate cancer (PCa). All patients received either empiric PAP with four doses of cotrimoxazole 960\u00a0mg or targeted antibiotic prophylaxis in case of a positive rectal or urine screening for multiresistant gram-negatives. Infectious complications after TRPB, microbiological findings, and clinical characteristics were evaluated. A multivariable logistic regression model was calculated to identify variables associated with infectious complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the cohort, 86% (600\/697) received PAP with cotrimoxazole, 1% (8\/697) received cotrimoxazole plus an additional antibiotic, 4% (28\/697) received amoxicillin\u2009+\u2009clavulanic acid, 4% (28\/697) received fluoroquinolones, and 5% (33\/697) received a single shot intravenous antibiotic prophylaxis with meropenem or piperacillin\u2009+\u2009tazobactam due to multiresistant microbiological findings in either pre-interventional urine culture or rectal swab. Infectious complications occurred in 2.6% (18\/697) of patients. Fever was noted in 89% (16\/18) of cases. Inpatient treatment was given to 67% (12\/18) of affected patients, with 38% (7\/18) having positive blood cultures, identifying cotrimoxazole-resistant <jats:italic>E. coli<\/jats:italic> strains in six out of seven cases. Multivariable logistic regression analysis revealed no clinically significant variables, including PAP with cotrimoxazole, as independent risk factors for an infectious complication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using cotrimoxazole as PAP for TRPB in cases without multiresistant gram-negatives in pre-interventional urine cultures or rectal swabs seems feasible and practical.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-04969-4","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:04:10Z","timestamp":1714061050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cotrimoxazole and targeted antibiotic prophylaxis for transrectal prostate biopsy: a single-center study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-2595","authenticated-orcid":false,"given":"Matthias","family":"Jahnen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Amiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kirchoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Herkommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin H.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Lunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"4969_CR1","unstructured":"EAU Guidelines Edn (2023) Presented at the EAU Annual Congress Milan"},{"issue":"3","key":"4969_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/JU.0000000000001399","volume":"205","author":"B Pradere","year":"2021","unstructured":"Pradere B et al (2021) Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol 205(3):653\u2013663","journal-title":"J Urol"},{"issue":"1","key":"4969_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bju.15039","volume":"126","author":"B Berry","year":"2020","unstructured":"Berry B et al (2020) Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int 126(1):97\u2013103","journal-title":"BJU Int"},{"issue":"4","key":"4969_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1023\/A:1007115312039","volume":"31","author":"K Isen","year":"1999","unstructured":"Isen K et al (1999) Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole. Int Urol Nephrol 31(4):491\u2013495","journal-title":"Int Urol Nephrol"},{"key":"4969_CR5","unstructured":"European medicines agency (2018) E.m., Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics (EMA\/795349\/2018)"},{"issue":"2","key":"4969_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/JU.0000000000000814","volume":"204","author":"A Pilatz","year":"2020","unstructured":"Pilatz A et al (2020) Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol 204(2):224\u2013230","journal-title":"J Urol"},{"issue":"11\u201312","key":"4969_CR7","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.5489\/cuaj.3068","volume":"9","author":"V Sen","year":"2015","unstructured":"Sen V et al (2015) The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: a prospective, randomized, and controlled clinical study. Can Urol Assoc J 9(11\u201312):E863\u2013E867","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"4969_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/iju.13883","volume":"26","author":"J Van Besien","year":"2019","unstructured":"Van Besien J et al (2019) Use of fosfomycin as targeted antibiotic prophylaxis before prostate biopsy: a prospective randomized study. Int J Urol 26(3):391\u2013397","journal-title":"Int J Urol"},{"issue":"1","key":"4969_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13756-015-0047-6","volume":"4","author":"J M\u00fcller","year":"2015","unstructured":"M\u00fcller J et al (2015) Cross-border comparison of the Dutch and German guidelines on multidrug-resistant Gram-negative microorganisms. Antimicrob Resist Infect Control 4(1):7","journal-title":"Antimicrob Resist Infect Control"},{"key":"4969_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.12688\/f1000research.19260.1","volume":"9","author":"J Styrke","year":"2020","unstructured":"Styrke J et al (2020) Current routines for antibiotic prophylaxis prior to transrectal prostate biopsy: a national survey to all urology clinics in Sweden. F1000Res 9:58","journal-title":"F1000Res"},{"issue":"2","key":"4969_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00120-021-01618-1","volume":"61","author":"K Rothe","year":"2022","unstructured":"Rothe K et al (2022) Antibiotic prophylaxis for transrectal prostate biopsy: in the context of restricted indications for fluoroquinolones and antibiotic stewardship. Urologe A 61(2):160\u2013166","journal-title":"Urologe A"},{"issue":"Suppl","key":"4969_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijantimicag.2011.09.004","volume":"38","author":"FM Wagenlehner","year":"2011","unstructured":"Wagenlehner FM, Wullt B, Perletti G (2011) Antimicrobials in urogenital infections. Int J Antimicrob Agents 38(Suppl):3\u201310","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"4969_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00345-018-2319-2","volume":"36","author":"AM Elshal","year":"2018","unstructured":"Elshal AM et al (2018) Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial. World J Urol 36(11):1845\u20131852","journal-title":"World J Urol"},{"issue":"3","key":"4969_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.prnil.2016.06.001","volume":"4","author":"A Fahmy","year":"2016","unstructured":"Fahmy A et al (2016) Optimizing prophylactic antibiotic regimen in patients admitted for transrectal ultrasound-guided prostate biopsies: a prospective randomized study. Prostate Int 4(3):113\u2013117","journal-title":"Prostate Int"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04969-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:27:49Z","timestamp":1735853269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04969-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4969"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04969-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias Jahnen, Florian Kirchoff, Jacob W. B\u00fcchler, Kathleen Herkommer, Kathrin Rothe, Valentin H. Meissner, J\u00fcrgen E. Gschwend, and Lukas Lunger have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Technical University of Munich.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"260"}}